CytomX Therapeutics, Inc.
CTMX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -68% | -63.4% | 33.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -235.4% | -5% | 45.2% | 47.5% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -238.6% | -0.8% | 46.2% | 49.6% |
| EPS Diluted | -0.09 | -0.001 | 0.27 | 0.24 |
| % Growth | -7,400% | -100.4% | 12.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |